How to Get Rezdiffra (Resmetirom) in Alabama

What Is Rezdiffra and Why Does It Matter for Alabama Patients?

Rezdiffra (resmetirom) is the first and, as of early 2026, only FDA-approved medication targeting MASH with liver fibrosis. Madrigal Pharmaceuticals received accelerated approval in March 2024 based on histological endpoints from the MAESTRO-NASH trial, which demonstrated resolution of steatohepatitis without worsening of fibrosis in a significant proportion of treated patients.

Alabama carries a disproportionate burden of the conditions that drive MASH. The state ranks among the highest nationally for obesity prevalence, with the CDC reporting adult obesity rates exceeding 39% in recent surveys. Type 2 diabetes, another major risk factor, affects roughly 15% of Alabama adults according to CDC diabetes surveillance data. These overlapping metabolic conditions make MASH underdiagnosed and undertreated across the state, particularly in rural counties with limited hepatology access.

In the MAESTRO-NASH phase 3 trial, resmetirom 100 mg daily achieved MASH resolution (without fibrosis worsening) in 29.9% of patients at 52 weeks, compared with 9.7% on placebo [1]. The 80 mg dose achieved a 25.9% resolution rate. Both doses also met the co-primary endpoint of at least one stage of fibrosis improvement without NASH worsening [1]. These results apply directly to Alabama patients with biopsy-confirmed MASH and fibrosis stages F2 or F3, which represents the FDA-approved indication.

Telehealth Prescribing for Rezdiffra in Alabama

Alabama law permits telehealth prescribing of Rezdiffra. This is a direct access pathway for patients in underserved or rural counties. The Alabama Board of Medical Examiners allows physicians to establish a patient-provider relationship via synchronous audio-video visits, and nurse practitioners with full prescriptive authority (granted after a collaborative period under Alabama's NP practice laws) can also prescribe.

A telehealth visit for resmetirom typically involves three steps. First, the provider reviews existing labs and imaging, including liver function tests, FIB-4 index, and, if available, FibroScan or MRI-PDFF results. Second, the clinician confirms the MASH diagnosis and fibrosis stage, often requiring a prior liver biopsy or validated noninvasive test. Third, the provider submits the prescription electronically to a specialty or 503A pharmacy licensed to ship within Alabama.

Patients in counties like Dallas, Wilcox, or Greene, where the nearest gastroenterologist may be 90 minutes away, benefit most from this pathway. The American Association for the Study of Liver Diseases (AASLD) has noted that telehealth expansion is one mechanism to close gaps in liver disease care across the rural South.

Expect the initial telehealth consultation to take 30 to 45 minutes. Follow-up visits are shorter, typically 15 to 20 minutes, focused on lab monitoring and side effect assessment. Most telehealth platforms require patients to have baseline labs drawn at a local Quest, LabCorp, or hospital lab before the first appointment.

Required Labs Before Starting Resmetirom in Alabama

Before any Alabama provider writes a Rezdiffra prescription, a specific lab panel is necessary. The FDA label and clinical practice require baseline values that serve both diagnostic and safety purposes.

The minimum baseline labs include a comprehensive metabolic panel (CMP) with ALT, AST, and alkaline phosphatase; a complete blood count (CBC); thyroid function tests (TSH and free T4); a lipid panel; and HbA1c. Resmetirom is a thyroid hormone receptor beta (THR-beta) agonist, so thyroid monitoring is mandatory. In MAESTRO-NASH, resmetirom reduced LDL cholesterol by approximately 14% at the 100 mg dose [1], which means baseline lipids also help track therapeutic response.

The FDA prescribing information recommends checking thyroid function before initiation and periodically during treatment. Patients with uncontrolled hypothyroidism or hyperthyroidism were excluded from the key trial, so thyroid status must be stable before starting.

For fibrosis staging, providers typically require one of the following: a liver biopsy performed within the prior 24 months showing F2 or F3 fibrosis, a FibroScan with a liver stiffness measurement between 8.0 and 13.9 kPa (corresponding roughly to F2-F3), or an enhanced liver fibrosis (ELF) score. The NIH-sponsored NASH Clinical Research Network has published scoring systems that many Alabama hepatologists reference for noninvasive assessment.

After starting resmetirom, labs are rechecked at 12 weeks and then every 6 months. ALT reductions of 30% or more from baseline are a common early response signal. In MAESTRO-NASH, the 100 mg dose reduced ALT by a mean of 22% at week 24 [1].

Pharmacy Access and 503A Compounding in Alabama

Alabama patients have two main pharmacy pathways for obtaining Rezdiffra: specialty pharmacies carrying the branded product from Madrigal and 503A compounding pharmacies that may prepare resmetirom formulations.

Specialty pharmacy distribution is the primary channel. Madrigal uses a limited distribution network, meaning only certain pharmacies stock Rezdiffra. Patients in Birmingham, Huntsville, Mobile, and Montgomery are most likely to find local specialty pharmacies enrolled in the distribution program. For patients outside these metros, mail-order specialty pharmacy is the standard route. Turnaround from prescription submission to delivery typically runs 5 to 10 business days, though prior authorization delays can extend this.

Alabama's 503A compounding pharmacies operate under state Board of Pharmacy oversight and may compound resmetirom if they obtain the active ingredient from an FDA-registered supplier. The FDA's compounding framework under Section 503A of the Federal Food, Drug, and Cosmetic Act permits patient-specific compounding based on a valid prescription. Not all Alabama compounders stock resmetirom, so patients should confirm availability before transferring a prescription.

A key distinction: 503A pharmacies compound for individual patients based on a prescription, while 503B outsourcing facilities compound in bulk without patient-specific prescriptions. Alabama patients using 503A pharmacies need a prescription that names them specifically. Cost through a compounder can be lower than branded Rezdiffra, but insurance typically does not reimburse compounded versions. The branded product, Rezdiffra, carries a list price of approximately $47,400 per year before insurance and copay programs.

Insurance Coverage and Prior Authorization in Alabama

Alabama Medicaid does not cover Rezdiffra as of 2026. This leaves an estimated 900,000 Medicaid enrollees without a public insurance pathway to the drug. Patients on Alabama Medicaid who need resmetirom must pursue manufacturer assistance or alternative coverage.

Commercial insurers in Alabama, including Blue Cross Blue Shield of Alabama, Viva Health, and UnitedHealthcare plans offered through the federal marketplace, generally require prior authorization. The documentation package for PA typically includes four components: confirmed MASH diagnosis with histological or noninvasive evidence, fibrosis staging showing F2 or F3, documentation that lifestyle modifications (diet, exercise, weight management) were attempted for at least 6 months, and baseline lab values including liver enzymes and thyroid function.

Some insurers also require that the prescribing physician be a hepatologist, gastroenterologist, or endocrinologist. A primary care physician's prescription may trigger an additional review step. Prior authorization decisions in Alabama typically take 5 to 15 business days for commercial plans. Denials can be appealed, and the Endocrine Society's clinical guidelines and AASLD practice guidance serve as supporting evidence in appeal letters.

Madrigal offers the Rezdiffra Complete program, which includes copay assistance for commercially insured patients (reducing out-of-pocket costs to as low as $0 per month for eligible patients) and a patient assistance program for uninsured individuals. Patients can verify eligibility through their prescribing provider or the specialty pharmacy.

Who Can Prescribe Rezdiffra in Alabama?

Three categories of licensed prescribers in Alabama can write a Rezdiffra prescription. Each has different regulatory requirements and scopes of practice.

Physicians (MDs and DOs) have unrestricted prescriptive authority in Alabama. Hepatologists and gastroenterologists are the most common prescribers given the liver-specific indication, but any licensed Alabama physician can legally prescribe resmetirom. In practice, some insurers prefer or require a specialist prescription for prior authorization approval.

Nurse practitioners (NPs) in Alabama gained full practice authority under the Alabama Nurse Practice Act as amended, though newer NPs must complete a collaborative period. An NP with independent prescriptive authority can prescribe Rezdiffra, order the required labs, and manage ongoing monitoring. According to AAFP state practice environment data, Alabama NPs represent a significant portion of primary care providers in rural regions, making them an important access point.

Physician assistants (PAs) in Alabama prescribe under a collaborative agreement with a supervising physician. A PA working in a gastroenterology or hepatology practice can prescribe resmetirom provided the supervising physician approves the prescriptive authority for that drug class. The prescription must comply with the Alabama Board of Medical Examiners collaborative practice requirements.

Timeline from Consultation to Receiving Rezdiffra in Alabama

The total time from initial consultation to receiving Rezdiffra in Alabama varies from 2 weeks (best case) to 8 weeks or more, depending on insurance and pharmacy logistics. Here is a realistic breakdown.

Week 1 covers the initial consultation and lab work. Whether through telehealth or an in-person visit, the provider evaluates the patient, orders labs, and reviews prior records. Lab results from Quest or LabCorp are typically available within 2 to 3 business days. FibroScan results, if needed, may require scheduling at a facility in Birmingham, Huntsville, or Mobile, potentially adding a week.

Weeks 2 through 3 involve prescription submission and prior authorization. The provider sends the prescription to a specialty pharmacy and initiates PA. Straightforward cases with clear documentation may receive approval within 5 business days. Complex cases, especially those where the insurer questions fibrosis staging or requests peer-to-peer review, can take 10 to 15 business days.

Weeks 3 through 4 cover pharmacy processing and shipment. Once PA is approved, the specialty pharmacy contacts the patient to confirm shipping details, process copay assistance enrollment, and arrange delivery. Most Alabama patients receive the medication via FedEx or UPS cold-chain shipping within 3 to 5 business days after pharmacy processing.

If PA is denied, add 2 to 4 weeks for an appeal. The appeal success rate for MASH therapies in commercial plans has been estimated at 40% to 60% when supported by biopsy data and guideline-concordant documentation, based on published analyses of specialty drug access patterns.

Transferring a Rezdiffra Prescription to Alabama

Patients relocating to Alabama or receiving care across state lines can transfer an existing Rezdiffra prescription. Alabama accepts prescription transfers from other states through the standard pharmacy transfer process, provided the originating prescription is valid and written by a licensed prescriber.

The receiving Alabama pharmacy contacts the sending pharmacy to verify the prescription, remaining refills, and prescriber information. For specialty medications like Rezdiffra on limited distribution, the transfer must go to a pharmacy enrolled in Madrigal's distribution network. A patient cannot transfer a Rezdiffra prescription to a standard retail pharmacy.

Telehealth prescriptions written by out-of-state providers require that the prescriber hold an Alabama medical license or that the patient be seen by an Alabama-licensed provider who can write a new prescription. The Interstate Medical Licensure Compact, which Alabama has joined, simplifies multi-state licensure for physicians but does not automatically authorize prescribing in Alabama without the appropriate compact license.

Patients transferring care should bring their most recent liver biopsy report, FibroScan results, and at least 6 months of lab trends (ALT, AST, thyroid function) to the new Alabama provider. This documentation reduces the likelihood of repeat testing and accelerates the prescribing process.

Side Effects and Monitoring Considerations

Resmetirom's safety profile in MAESTRO-NASH showed the most common adverse events were diarrhea (occurring in approximately 27% of patients on the 100 mg dose vs. 16% on placebo) and nausea (reported in approximately 22% vs. 13%) [1]. These gastrointestinal effects were generally mild to moderate and tended to decrease after the first 4 to 8 weeks of treatment according to the FDA label.

Given resmetirom's mechanism as a selective THR-beta agonist, thyroid-related adverse effects were monitored closely. The drug is designed to spare the THR-alpha receptor (which mediates cardiac effects), and in the trial, heart rate increases were minimal and not clinically significant [1]. TSH levels remained stable in most patients, though periodic monitoring is still recommended per the label.

Alabama providers should monitor hepatic function closely during the first 12 weeks. Any ALT elevation exceeding 5 times the upper limit of normal warrants temporary discontinuation and hepatology consultation. The AASLD recommends liver enzyme checks at baseline, week 12, and every 6 months thereafter for patients on resmetirom.

Drug interactions are limited but notable. Resmetirom may increase the metabolism of certain statins; patients on atorvastatin or rosuvastatin should have lipid panels rechecked 8 to 12 weeks after starting resmetirom. The prescribing information also advises caution with strong CYP2C8 inhibitors, which can increase resmetirom exposure by up to 2-fold according to pharmacokinetic data from the FDA review.

Cost Reduction Strategies for Alabama Patients

The annual list price of Rezdiffra (approximately $47,400) puts it out of reach for most uninsured patients. Several cost-reduction pathways exist for Alabama residents.

Madrigal's copay assistance program covers most or all out-of-pocket costs for commercially insured patients, often reducing the monthly copay to $0. Eligibility requires commercial insurance (not government-funded plans like Medicaid, Medicare, or Tricare). The program is accessed through the specialty pharmacy at the time of prescription fill.

For uninsured patients, Madrigal offers a patient assistance program (PAP) that provides the drug at no cost to qualifying individuals. Income thresholds apply, generally set at or below 400% of the federal poverty level. Application requires proof of income, a valid prescription, and documentation of insurance denial or lack of coverage.

503A compounding may offer a lower-cost alternative, though patients should understand the trade-offs. Compounded resmetirom has not undergone the same bioequivalence testing as the branded product, and insurance will not cover it. Prices at Alabama 503A pharmacies range widely, but some patients report paying between $200 and $600 per month. A study published in Annals of Internal Medicine found that compounded medications can vary in potency by up to 25%, reinforcing the need to use reputable, accredited compounders.

Medicare Part D plans may cover Rezdiffra with prior authorization, though formulary placement varies by plan. Alabama Medicare beneficiaries should check their specific plan's formulary or contact 1-800-MEDICARE to confirm coverage status.